660 related articles for article (PubMed ID: 22630093)
1. Activity of beta-lactam beta-lactamase inhibitor combinations against extended spectrum Beta-lactamase producing Enterobacteriaceae in urinary isolates.
Afridi FI; Farooqi BJ
J Coll Physicians Surg Pak; 2012 Jun; 22(6):358-62. PubMed ID: 22630093
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
Mohanty S; Singhal R; Sood S; Dhawan B; Das BK; Kapil A
Indian J Med Res; 2005 Nov; 122(5):425-8. PubMed ID: 16456257
[TBL] [Abstract][Full Text] [Related]
3. Comparative in-vitro activity of cefoperazone-tazobactam and cefoperazone-sulbactam combinations against ESBL pathogens in respiratory and urinary infections.
Patankar M; Sukumaran S; Chhibba A; Nayak U; Sequeira L
J Assoc Physicians India; 2012 Nov; 60():22-4. PubMed ID: 23767198
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam.
Peterson LR
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():181-4. PubMed ID: 18154544
[TBL] [Abstract][Full Text] [Related]
5. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
Nomura S; Hanaki H; Nagayama A
J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
Sader HS; Tosin I; Sejas L; Miranda E
Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
[TBL] [Abstract][Full Text] [Related]
7. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
[TBL] [Abstract][Full Text] [Related]
8. Management of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: current evidence and future prospects.
Sheu CC; Lin SY; Chang YT; Lee CY; Chen YH; Hsueh PR
Expert Rev Anti Infect Ther; 2018 Mar; 16(3):205-218. PubMed ID: 29402125
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
[TBL] [Abstract][Full Text] [Related]
10. Occurrence of ESBL & Amp-C beta-lactamases & susceptibility to newer antimicrobial agents in complicated UTI.
Taneja N; Rao P; Arora J; Dogra A
Indian J Med Res; 2008 Jan; 127(1):85-8. PubMed ID: 18316858
[TBL] [Abstract][Full Text] [Related]
11. Frequency of extended spectrum beta lactamase producing enterobacteriaceae among urinary pathogen isolates.
Afridi FI; Farooqi BJ; Hussain A
J Coll Physicians Surg Pak; 2011 Dec; 21(12):741-4. PubMed ID: 22166694
[TBL] [Abstract][Full Text] [Related]
12. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI screening parameters for the detection of extended-spectrum β-lactamase production in clinical Enterobacteriaceae isolates.
Polsfuss S; Bloemberg GV; Giger J; Meyer V; Hombach M
J Antimicrob Chemother; 2012 Jan; 67(1):159-66. PubMed ID: 21972269
[TBL] [Abstract][Full Text] [Related]
13. Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations.
Thomson KS; Weber DA; Sanders CC; Sanders WE
Antimicrob Agents Chemother; 1990 Apr; 34(4):622-7. PubMed ID: 2344169
[TBL] [Abstract][Full Text] [Related]
14. Non-carbapenem therapy of urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae.
de La Blanchardière A; Dargère S; Guérin F; Daurel C; Saint-Lorant G; Verdon R; Cattoir V
Med Mal Infect; 2015 May; 45(5):169-72. PubMed ID: 25845927
[TBL] [Abstract][Full Text] [Related]
15. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M
J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and antimicrobial susceptibility pattern of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the United Arab Emirates.
Al-Zarouni M; Senok A; Rashid F; Al-Jesmi SM; Panigrahi D
Med Princ Pract; 2008; 17(1):32-6. PubMed ID: 18059098
[TBL] [Abstract][Full Text] [Related]
17. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
Aris P; Boroumand MA; Rahbar M; Douraghi M
Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
[TBL] [Abstract][Full Text] [Related]
18. [Extended-spectrum beta-lactamase production by Enterobacteriaceae isolates from urine cultures of outpatients: results of a 7-year follow-up].
Çelikbilek N; Gözalan A; Özdem B; Kırca F; Açıkgöz ZC
Mikrobiyol Bul; 2015 Apr; 49(2):259-65. PubMed ID: 26167826
[TBL] [Abstract][Full Text] [Related]
19. Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESBL- and AmpC β-lactamase-producing clinical Enterobacteriaceae isolates.
Hombach M; Mouttet B; Bloemberg GV
J Antimicrob Chemother; 2013 Sep; 68(9):2092-8. PubMed ID: 23633681
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility to penicillin derivatives among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission.
Mischnik A; Baumert P; Hamprecht A; Rohde A; Peter S; Feihl S; Knobloch J; Gölz H; Kola A; Obermann B; Querbach C; Willmann M; Gebhardt F; Tacconelli E; Gastmeier P; Seifert H; Kern WV;
Diagn Microbiol Infect Dis; 2017 Jan; 87(1):71-73. PubMed ID: 27769572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
